
Craig M Kessler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7467894/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129.	7.4	37
2	A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 139, 2931-2941.	1.4	45
3	Development of factor IX inhibitor in an adult with severe haemophilia B following COVIDâ€19 vaccination: A case report. Haemophilia, 2022, 28, .	2.1	1
4	Immune thrombocytopenia in the elderly: immunosenescent and clinical diversity. British Journal of Haematology, 2022, 196, 1134-1136.	2.5	1
5	The role of total ankle replacement in patients with haemophilia and endâ€stage ankle arthropathy: A review. Haemophilia, 2021, 27, 184-191.	2.1	7
6	Thrombocytopenia following Pfizer and Moderna <scp>SARS oV</scp> â€2 vaccination. American Journal of Hematology, 2021, 96, 534-537.	4.1	331
7	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq1 2021, 27, 911-920.	1 0.78431 2.1	l4 rgBT /Ονe 5
8	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	2.1	7
9	Emicizumab for the Treatment of Acquired Hemophilia a: A Multicenter US Case Series. Blood, 2021, 138, 496-496.	1.4	7
10	Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency during Surgery or Childbirth. Blood, 2021, 138, 3238-3238.	1.4	0
11	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood, 2021, 138, 586-586.	1.4	1
12	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia, 2020, 26, 966-974.	2.1	4
13	International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica, 2020, 105, 1791-1801.	3.5	182
14	Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation. JTO Clinical and Research Reports, 2020, 1, 100049.	1.1	5
15	Highlights in nonmalignant hematology from the 2019 American Society of Hematology meeting. Clinical Advances in Hematology and Oncology, 2020, 18, 86-88.	0.3	0
16	Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Therapeutic Advances in Hematology, 2019, 10, 204062071985847.	2.5	18
17	Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement. Haemophilia, 2019, 25, 969-978.	2.1	24
18	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 2019, 134, 1498-1509.	1.4	123

#	Article	IF	CITATIONS
19	Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1343-1345.	1.3	17
20	Longâ€ŧerm risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to dâ€dimer results; A cohort study. Journal of Thrombosis and Haemostasis, 2019, 17, 1144-1152.	3.8	34
21	Publishing in Haemophilia. Haemophilia, 2019, 25, 181-182.	2.1	2
22	Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews, 2019, 35, 43-50.	5.7	57
23	Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective nonâ€interventional study in a realâ€world setting. Haemophilia, 2019, 25, 213-220.	2.1	31
24	The effect of emicizumab prophylaxis on healthâ€related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia, 2019, 25, 33-44.	2.1	63
25	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. Blood, 2019, 134, 2943-2943.	1.4	4
26	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thrombosis and Haemostasis, 2018, 118, 451-460.	3.4	22
27	Impact of hemophilia B on quality of life in affected men, women, and caregivers—Assessment of patientâ€reported outcomes in the Bâ€ <scp>HERO</scp> â€S study. European Journal of Haematology, 2018, 100, 592-602.	2.2	30
28	Patientâ€reported outcomes and joint status across subgroups of <scp>US</scp> adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 14-24.	2.2	10
29	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patientâ€reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 5-13.	2.2	37
30	Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation. Seminars in Thrombosis and Hemostasis, 2018, 44, 813-822.	2.7	7
31	Reliability and validity of patientâ€reported outcome instruments in US adults with hemophilia B and caregivers in the Bâ€HEROâ€S study. European Journal of Haematology, 2018, 101, 781-790.	2.2	7
32	Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim. Blood, 2018, 132, 735-735.	1.4	11
33	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2018, 132, 3032-3032.	1.4	6
34	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	1.4	39
35	Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study. Blood, 2018, 132, 383-383.	1.4	1
36	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. Blood, 2018, 132, 2479-2479.	1.4	0

#	Article	IF	CITATIONS
37	Feasibility of the Von Willebrand disease PREVENT trial. Thrombosis Research, 2017, 156, 8-13.	1.7	9
38	Management of <scp>US</scp> men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€ <scp>HERO</scp> â€\$) study. European Journal of Haematology, 2017, 98, 5-17.	2.2	25
39	Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1831-1839.	1.8	27
40	The Coags Uncomplicated App: Fulfilling Educational Gaps Around Diagnosis and Laboratory Testing of Coagulation Disorders. JMIR Medical Education, 2017, 3, e6.	2.6	3
41	Assessment of acquired hemophilia patient demographics in the United States. Blood Coagulation and Fibrinolysis, 2016, 27, 761-769.	1.0	39
42	A second retrospective database analysis confirms prior findings of apparent increased cardiovascular comorbidities in hemophilia <scp>A</scp> in the <scp>U</scp> nited <scp>S</scp> tates. American Journal of Hematology, 2016, 91, E298-9.	4.1	11
43	Baby hamster kidney cell–derived recombinant factor VIII: a quarter century of learning and clinical experience. Expert Review of Hematology, 2016, 9, 1151-1164.	2.2	2
44	Impact of Mild to Severe Hemophilia B on Quality of Life Including Pain and Functional Abilities in Affected Men/Women and Caregivers of Affected Boys/Girls: Analysis of Patient Reported Outcomes in the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study. Blood, 2016, 128, 251-251.	1.4	1
45	Relapsing Thrombotic Thrombocytopenic Purpura: A Single Center Experience. Blood, 2016, 128, 3732-3732.	1.4	Ο
46	Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentorâ,,¢2 Trial. Blood, 2016, 128, 2573-2573.	1.4	0
47	Acquired haemophilia: an overview for clinical practice. European Journal of Haematology, 2015, 95, 36-44.	2.2	82
48	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood, 2014, 123, 3887-3894.	1.4	112
49	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2014, 124, 2836-2836.	1.4	4
50	Economic Comparison Of Treating Hemophilia Patients Who Have Developed Inhibitors Via Immune Tolerance Induction Versus Prophylaxis and On-Demand Treatment With Bypassing Agents. Blood, 2013, 122, 422-422.	1.4	0
51	Use of objective efficacy criteria for evaluation of von willebrand factor/factor VIII concentrates. Blood Coagulation and Fibrinolysis, 2012, 23, 262-267.	1.0	4
52	US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry. Blood, 2012, 120, 3372-3372.	1.4	5
53	Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study. Blood, 2012, 120, 4624-4624.	1.4	4
54	The Hemostasis and Thrombosis Research Society (HTRS) Registry Study of Acquired Hemophilia: Assessment of AH Patient Demographics in the US. Blood, 2012, 120, 4625-4625.	1.4	1

#	Article	IF	CITATIONS
55	The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Thrombosis and Haemostasis, 2011, 106, 279-288.	3.4	30
56	Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,. Blood, 2011, 118, 3281-3281.	1.4	9
57	Recombinant Factor VIIa (rFVIIa) Is Safe and Effective When Used to Treat Acute Bleeding Episodes and to Prevent Bleeding During Surgery in Patients with Acquired Hemophilia: Updated Assessment From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Database,. Blood, 2011, 118, 3374-3374.	1.4	2
58	Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes, 2010, 3, 161.	1.4	149
59	Recent developments in topical thrombins. Thrombosis and Haemostasis, 2009, 102, 15-24.	3.4	33
60	Prevention of Venous Thromboembolism in Hospitalized Medical Patients. Cancer Investigation, 2009, 27, 17-27.	1.3	1
61	International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica, 2009, 94, 566-575.	3.5	362
62	The Link Between Cancer and Venous Thromboembolism. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, S3-S7.	1.3	45
63	Treatment of Acute Bleeds in Acquired Hemophilia: An Updated Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry Blood, 2009, 114, 3499-3499.	1.4	Ο
64	Treatment of Acute Bleeds in Acquired Hemophilia: Analysis from the Hemophilia Research Society (HRS) and Hemophilia and Thrombosis Research Society (HTRS) Registry Blood, 2008, 112, 2285-2285.	1.4	0
65	Advances in the treatment of hemophilia. Clinical Advances in Hematology and Oncology, 2008, 6, 184-7.	0.3	3
66	A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII Blood, 2007, 110, 783-783.	1.4	14
67	Von Willebrand Disease (VWD) - A Disease with Dual Factor Deficiencies- Discrepant FVIII:C Pharmacokinetic (PK) Characteristics in a Head to Head Trial of Two VWF/FVIII Concentrates Blood, 2007, 110, 2141-2141.	1.4	Ο
68	Update on Liver Disease in Hemophilia Patients. Seminars in Hematology, 2006, 43, S13-S17.	3.4	9
69	Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstetricia Et Gynecologica Scandinavica, 2006, 85, 1239-1247.	2.8	35
70	Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. American Journal of Hematology, 2006, 81, 582-589.	4.1	43
71	The Impact of GM-CSF on Arsenic Trioxide (As2O3, Trisenox) Therapy in Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase II Study Blood, 2006, 108, 4856-4856.	1.4	1
72	New Perspectives in Hemophilia Treatment. Hematology American Society of Hematology Education Program, 2005, 2005, 429-435.	2.5	49

#	Article	IF	CITATIONS
73	Antidotes to haemorrhage: recombinant factor VIIa. Best Practice and Research in Clinical Haematology, 2004, 17, 183-197.	1.7	7
74	Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 348, 1425-1434.	27.0	771
75	Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood, 2002, 99, 450-456.	1.4	188
76	Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate. Annals of Internal Medicine, 2002, 137, 884.	3.9	244
77	Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?. Intensive Care Medicine, 2002, 28, s228-s234.	8.2	22
78	New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Current Opinion in Hematology, 2000, 7, 408-413.	2.5	34
79	Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate. American Journal of Hematology, 1992, 40, 210-215.	4.1	33
80	Anticoagulation and Thrombolytic Therapy. Chest, 1989, 95, 245S-256S.	0.8	6